Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium 10 mcg/puff
Drug: Tiotropium 0.625 mcg/puff
Drug: Tiotropium 5 mcg/puff
Drug: Tiotropium-18 lactose powder
Drug: Tiotropium 2.5 mcg/puff
Drug: Placebo solution
Drug: Placebo lactose powder
Drug: Tiotropium 1.25 mcg/puff
Device: Respimat
Device: Handihaler

First Posted Date: 2014-06-26

Last Posted Date: 2025-01-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 202

Registration Number: NCT02175342

Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH)

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Placebo
Drug: Medium dose of Micardis®
Drug: Low dose of Micardis®
Drug: High dose of Micardis®
Drug: Hydrochlorothiazide

First Posted Date: 2014-06-26

Last Posted Date: 2014-07-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1039

Registration Number: NCT02175355

Safety and Tolerability of COMBIVENT® HFA as Compared to COMBIVENT® CFC and Placebo HFA in Healthy Male and Female Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: COMBIVENT® HFA-MDI
Drug: COMBIVENT® CFC-MDI
Drug: Placebo HFA-MDI

First Posted Date: 2014-06-25

Last Posted Date: 2014-07-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT02173678

Efficacy and Safety of Tiotropium Compared to Salmeterol and Placebo in Patients With Chronic Obstructive Bronchitis (COPD)

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium inhalation powder capsules
Drug: Salmeterol inhalation aerosol
Drug: Placebo inhalation aerosol
Drug: Placebo inhalation powder capsules

First Posted Date: 2014-06-25

Last Posted Date: 2014-06-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 584

Registration Number: NCT02173691

BIBR 953 ZW in Healthy Elderly Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBR 1048 MS
Drug: Pantoprazole

First Posted Date: 2014-06-25

Last Posted Date: 2014-06-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT02173730

Relative Bioavailability of Single Doses of Dabigatran Etexilate in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Dabigatran etexilate
Drug: Rifampicin

First Posted Date: 2014-06-25

Last Posted Date: 2014-06-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02173717

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS Administered to Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI 1356 BS - Tablet
Drug: BI 1356 BS - Powder in bottle (PIB)

First Posted Date: 2014-06-25

Last Posted Date: 2014-07-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 64

Registration Number: NCT02173665

Changes in Physical Functioning in Patients With COPD During Therapy With a Combination Inhalation Therapy

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Spiriva® Respimat®
Drug: Striverdi® Respimat®

First Posted Date: 2014-06-25

Last Posted Date: 2017-06-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1845

Registration Number: NCT02173769

Locations: 🇩🇪
Boehringer Ingelheim Investigational Site 2, Ahaus, Germany
🇩🇪
Boehringer Ingelheim Investigational Site 11, Aßlar, Germany
🇩🇪
Boehringer Ingelheim Investigational Site 78, Bonn, Germany

and more 698 locations

Berodual® Respimat® Versus Berodual® Metered Aerosol (MA) Inhaler in Patients With Asthma, Chronic Obstructive Pulmonary Disease, or Mixed Condition

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive
Asthma

Interventions: Drug: Berodual® Respimat®
Drug: Berodual® MA HFA

First Posted Date: 2014-06-25

Last Posted Date: 2014-07-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 245

Registration Number: NCT02173795

Comparison of Safety and Efficacy of Berodual® Administered Via the Respimat® Device With That Administered Via the Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Berodual® Respimat ® high dose
Drug: Berodual® MDI
Drug: Berodual® Respimat ® low dose
Drug: Placebo

First Posted Date: 2014-06-25

Last Posted Date: 2014-07-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 892

Registration Number: NCT02173782

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy